Rhenman & Partners Asset Management’s Procept Biorobotics PRCT Stock Holding History

Rhenman & Partners Asset Management’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.79M	Sell	345,000 -130,000	-27%	-$3.25M	0.74%	55
2026 Q1	$11.9M	Sell	475,000 -136,000	-22%	-$3.83M	1.47%	23
2025 Q4	$19.2M	Buy	611,000 +221,000	+57%	+$7.33M	1.8%	18
2025 Q3	$13.9M	Buy	390,000 +200,000	+105%	+$9.13M	1.54%	27
2025 Q2	$10.9M	Sell	190,000 -258,000	-58%	-$14.6M	1.38%	29
2025 Q1	$26.1M	Buy	448,000 +27,655	+7%	+$1.89M	3%	8
2024 Q4	$33.8M	Sell	420,345 -24,655	-6%	-$2.11M	3.48%	3
2024 Q3	$35.7M	Buy	445,000 +5,000	+1%	+$355K	2.89%	6
2024 Q2	$26.9M	Sell	440,000 -47,063	-10%	-$2.8M	2.58%	11
2024 Q1	$24.1M	Buy	487,063 +177,063	+57%	+$8.43M	2.28%	14
2023 Q4	$13M	Sell	310,000 -183,000	-37%	-$6.23M	1.3%	29
2023 Q3	$16.2M	Buy	493,000 +214,000	+77%	+$7.3M	1.74%	24
2023 Q2	$9.86M	Buy	+279,000	New	+$9.22M	1.04%	35

Other funds holding PRCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rhenman & Partners Asset Management's PRCT Position: Q2 2026 in Review

Rhenman & Partners Asset Management reduced its Procept Biorobotics (PRCT) stake by 27% in Q2 2026, selling an estimated $3.25M and leaving 345,000 shares worth $7.79M. The position accounts for 0.74% of the portfolio, ranked #55.

Rhenman & Partners Asset Management first reported a position in PRCT in Q2 2023 and has held it in 13 quarters since. The position peaked at $35.7M in Q3 2024. 253 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

Rhenman & Partners Asset Management held 345,000 shares of Procept Biorobotics worth $7.79M as of Q2 2026.
Rhenman & Partners Asset Management sold 130,000 Procept Biorobotics shares in Q2 2026, an estimated $3.25M.
Procept Biorobotics made up 0.74% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #55 holding.
Rhenman & Partners Asset Management first reported a position in Procept Biorobotics in Q2 2023 and has held it in 13 quarters since.
Rhenman & Partners Asset Management's Procept Biorobotics position peaked at $35.7M in Q3 2024.
253 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.